glp-1 price cut news november 2025 Weight-loss drug makers announce pricing agreement with Trump Patients Face New Barriers for

The primary legal issue could be whether the Ozempic manufacturer, Novo Nordisk, knew or should have known about the heightened risks for NAION vision impairment that these drugs posed to users and failed to warn doctors and patients of this risk

Research suggests that the healthcare industry treats fat patients worse than skinny ones and that fat people are also discriminated against at work and school

Along with helping to control blood sugar and boost weight loss, GLP-1s and SGLT-2 inhibitors seem to have other major benefits

I highly recommend her to anyone looking for someone who truly goes above and beyond with a lovely, thoughtful approach

That is enough to materially chill the category at scale

If you plan to become pregnant, discuss discontinuation of Saxenda with your healthcare provider well in advance